Sugi Predict

Sugi Predict / Compounds / SCHEMBL29520161

SCHEMBL29520161

SCHEMBL29520161

O=C(Cc1ccccc1)Nc1cccc(O)c1

nearest known ligand 0.75

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ NLRP3 Q96P20 13/20 0.75
▸ EPHX2 P34913 1/20 0.71
▸ KMT2A Q03164 2/20 0.68
▸ USP2 O75604 2/20 0.64
▸ ALDH1A1 P00352 2/20 0.64
▸ SMN1; SMN2 Q16637 1/20 0.64
▸ LMNA P02545 1/20 0.64
▸ CFD P00746 1/20 0.62
▸ KDM4E B2RXH2 1/20 0.59
▸ MEN1 O00255 1/20 0.59
▸ POLB P06746 1/20 0.59
▸ MAPT P10636 1/20 0.59
▸ HPGD P15428 1/20 0.59
▸ BLM P54132 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4423342 1.00 NLRP3 (0.75) NLRP3EPHX2KMT2AUSP2ALDH1A1
SCHEMBL4423340 0.90 EPHX2 (0.71) NLRP3EPHX2KMT2AUSP2ALDH1A1
SCHEMBL11900270 0.90 EPHX2 (0.81) EPHX2KMT2AUSP2ALDH1A1SMN1; SMN2
SCHEMBL1516167 0.84 EPHX2 (1.00) EPHX2KMT2AUSP2ALDH1A1SMN1; SMN2
SCHEMBL31505906 0.83 EPHX2 (0.71) EPHX2KMT2AUSP2ALDH1A1SMN1; SMN2
SCHEMBL6100233 0.83 EPHX2 (0.71) NLRP3EPHX2KMT2AUSP2ALDH1A1
SCHEMBL6098738 0.83 CFD (0.81) EPHX2KMT2AUSP2ALDH1A1SMN1; SMN2
SCHEMBL26994660 0.83 EPHX2 (0.71) EPHX2KMT2AUSP2ALDH1A1SMN1; SMN2
SCHEMBL10052144 0.83 NLRP3 (0.70) NLRP3EPHX2KMT2AALDH1A1KDM4E
SCHEMBL2747679 0.83 KDM4E (0.62) NLRP3EPHX2KMT2AUSP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260035680-A1 THERAPEUTIC NUCLEASE COMPOSITIONS AND METHODS UNIV WASHINGTON (US) 2026-02-05 — — US disclosed
US-12435322-B2 Therapeutic nuclease compositions and methods UNIVERSITY OF WASHINGTON (US) 2025-10-07 — — US disclosed
US-20250277211-A1 LPA inhibitors and uses thereof KYLONOVA XIAMEN BIOPHARMA CO LTD (CN) 2025-09-04 — — US disclosed
US-20250223582-A1 ENGINEERED RNA LIGASES CODEXIS, INC. 2025-07-10 — — US disclosed
EP-4567112-A1 RNA INHIBITOR FOR INHIBITING APOC3 GENE EXPRESSION AND USE THEREOF Kylonova (Xiamen) Biopharma Co., Ltd. (CN) 2025-06-11 — — EP disclosed
CN-113862268-B AGT inhibitors and uses thereof 厦门甘宝利生物医药有限公司 2025-05-13 — — CN disclosed
US-20250066789-A1 AGT Inhibitor and Use Thereof KYLONOVA XIAMEN BIOPHARMA CO LTD (CN) 2025-02-27 — — US disclosed
CN-119335777-A Liquid crystal display device having a light shielding layer 夏普显示科技株式会社 2025-01-21 — — CN disclosed
CN-119335778-A Liquid crystal display device having a light shielding layer 夏普显示科技株式会社 2025-01-21 — — CN disclosed
EP-4491727-A1 LPA INHIBITOR AND USE THEREOF Kylonova (Xiamen) Biopharma Co., Ltd. (CN) 2025-01-15 — — EP disclosed
US-11786598-B2 Lipid formulations for delivery of therapeutic agents ARBUTUS BIOPHARMA CORPORATION (CA) 2023-10-17 — — US disclosed
US-20230248831-A1 NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS ARBUTUS BIOPHARMA CORPORATION (CA) 2023-08-10 — — US disclosed
WO-2023066236-A1 AGT INHIBITOR AND USE THEREOF 厦门甘宝利生物医药有限公司 2023-04-27 — — WO disclosed
CN-115943209-A Methods and compositions for activating gamma-globin gene expression 广州瑞风生物科技有限公司 2023-04-07 — — CN disclosed
US-20230057085-A1 THERAPEUTIC NUCLEASE COMPOSITIONS AND METHODS UNIVERSITY OF WASHINGTON 2023-02-23 — — US disclosed
US-11478501-B2 Compositions and methods for inhibiting HMGB1 expression DICERNA PHARMACEUTICALS, INC. (US) 2022-10-25 — — US disclosed
US-11446383-B2 Lipid formulations for delivery of therapeutic agents ARBUTUS BIOPHARMA CORPORATION (CA) 2022-09-20 — — US disclosed
CN-114703184-A LPA inhibitor and use thereof 厦门甘宝利生物医药有限公司 2022-07-05 — — CN disclosed
WO-2022104367-A1 CELL-FREE EXPRESSION OF ANTIBODIES, ANTIGEN-BINDING FRAGMENTS THEREOF, AND ANTIBODY DERIVATIVES NORTHWESTERN UNIVERSITY (US) 2022-05-19 — — WO disclosed
US-11306297-B2 Therapeutic nuclease compositions and methods UNIVERSITY OF WASHINGTON (US) 2022-04-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230248831-A1 NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS PNLIP, NPC1L1, CETP NLRP3 4611/4885EPHX2 3146/4885KMT2A 1555/4885
US-11446383-B2 Lipid formulations for delivery of therapeutic agents CETP, PNLIP, NPC1L1 NLRP3 4575/4885EPHX2 3019/4885KMT2A 1530/4885
US-11478501-B2 Compositions and methods for inhibiting HMGB1 expression HMGB1, HMGB3, HMGB2 NLRP3 1975/4885EPHX2 1501/4885KMT2A 3388/4885
US-11786598-B2 Lipid formulations for delivery of therapeutic agents CETP, PNLIP, NPC1L1 NLRP3 4575/4885EPHX2 3019/4885KMT2A 1530/4885
US-20250066789-A1 AGT Inhibitor and Use Thereof AGT, AGTR1, AGTR2 NLRP3 4622/4885EPHX2 3030/4885KMT2A 1234/4885
US-20260035680-A1 THERAPEUTIC NUCLEASE COMPOSITIONS AND METHODS RNASE1, DNASE1L3, DNASE1 NLRP3 2143/4885EPHX2 2770/4885KMT2A 3468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.